<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01070238</url>
  </required_header>
  <id_info>
    <org_study_id>RA.4240.UKGiessen.021219.B</org_study_id>
    <nct_id>NCT01070238</nct_id>
  </id_info>
  <brief_title>Metabolic Response of Slow Released Carbohydrates in Diabetes Mellitus</brief_title>
  <official_title>Explorative, Pilot Study With Cross-over Design on the Metabolic Response of Orally Applied Slow Released Carbohydrates in Diabetes Type 2 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Numico Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Giessen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was conducted&#xD;
&#xD;
        1. to investigate the superiority of isomaltulose in reduction of postprandial&#xD;
           hyperglycemia&#xD;
&#xD;
        2. to describe the kinetics of glucose absorption after a load of isomaltulose&#xD;
&#xD;
        3. to demonstrate the safety of a single load of isomaltulose compared to sucrose in type 2&#xD;
           diabetic patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epidemiological studies have shown that postprandial hyperglycemia is associated with&#xD;
      atherosclerotic diseases. Therefore, therapeutic strategies to reduce postprandial&#xD;
      hyperglycemia are desirable. An effective way to improve postprandial glucose level is the&#xD;
      use of carbohydrates with low glycemic index. Isomaltulose is a reducing disaccharide&#xD;
      occurring naturally in honey and sugar cane juice, including products derived thereof. It is&#xD;
      an isomer of sucrose and composed of glucose and fructose linked alpha-1,6 instead of&#xD;
      alpha-1,2.&#xD;
&#xD;
      Isomaltulose has been reported to be digested more slowly than sucrose. Due to this property,&#xD;
      lower and slower increases in blood glucose responses are expected for isomaltulose than&#xD;
      sucrose. Early studies have demonstrated attenuated glycemic and insulin responses after&#xD;
      isomaltulose ingestion than after sucrose. This study was performed to describe the&#xD;
      postprandial glucose metabolism more comprehensively after bolus administration of different&#xD;
      doses of isomaltulose compared to sucrose in type 2 diabetic patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lower postprandial glucose and insulin responses after isomaltulose ingestion than after sucrose</measure>
  </primary_outcome>
  <condition>Type 2 Diabetes</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Isomaltulose</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis: type 2 diabetes according to WHO/ADA criteria for more than 1 yr&#xD;
&#xD;
          -  Adults aged 18-75 years old&#xD;
&#xD;
          -  HbA1c &lt; 8%, fasting blood glucose &lt; 140 mg/dl&#xD;
&#xD;
          -  For at least 2 months prior to visit 1, subjects must have been on a stable&#xD;
             antidiabetic therapy regimen&#xD;
&#xD;
          -  Subjects willing to perform home blood glucose monitoring and to otherwise comply with&#xD;
             study protocol requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes mellitus&#xD;
&#xD;
          -  Pregnant or lactating women or women planning to become pregnant&#xD;
&#xD;
          -  Women who become pregnant will be withdrawn from the study&#xD;
&#xD;
          -  Clinically significant heart, liver, lung, or kidney disease&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Concomitant therapy with systemic glucocorticoids or acarbose&#xD;
&#xD;
          -  Subjects unable to adhere to instructions during the qualification phase&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Giessen and Marburg</name>
      <address>
        <city>Giessen</city>
        <state>Hessen</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2002</verification_date>
  <study_first_submitted>February 16, 2010</study_first_submitted>
  <study_first_submitted_qc>February 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2010</study_first_posted>
  <last_update_submitted>February 16, 2010</last_update_submitted>
  <last_update_submitted_qc>February 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Thomas Linn/Principal Investigator</name_title>
    <organization>University of Giessen</organization>
  </responsible_party>
  <keyword>Isomaltulose</keyword>
  <keyword>Slow Released Carbohydrates</keyword>
  <keyword>Postprandial Glucose Metabolism</keyword>
  <keyword>Type 2 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

